Tag
A pooled analysis of three large cohorts found no consistent association between circulating lipoprotein(a) and Alzheimer’s disease or vascular dementia, but genetic evidence for very small apo(a) isoforms suggests a modest increase in Alzh
Autopsy of aducanumab-treated Alzheimer’s cases shows preferential clearance of superficial layer I amyloid, PET Centiloid reductions, and ARIA-associated microvascular pathology, implicating perivascular amyloid removal and vessel injury a
A large Mayo Clinic Study of Aging analysis shows lifetime and 10‑year absolute risk of MCI and dementia rise monotonically with amyloid PET centiloid values, modified by age, sex, and APOE ε4 status; out‑of‑study ascertainment substantiall
In cognitively unimpaired older adults with elevated amyloid, higher daily step counts were associated with slower inferior-temporal tau accumulation and attenuated cognitive and functional decline, with benefit plateauing around 5,000–7,50
An open-label two-year extension in five patients with mild Alzheimer’s disease found daily 1‑hour 40 Hz audiovisual stimulation to be safe, produced sustained EEG gamma entrainment in late‑onset cases, and was associated with smaller
This review synthesizes evidence on contactless, longitudinal sleep monitoring revealing Alzheimer’s disease-specific nocturnal behaviors and introduces the DRI-SI-AD digital biomarker for tracking dementia progression.
In an ADNI longitudinal cohort, persistently elevated depressive symptoms over 36 months after MCI diagnosis were associated with a dose‑dependent, substantially higher hazard of conversion to Alzheimer’s disease over long-term follow-up.
An expert Delphi consensus from ISTAART lays out core data, methods and research priorities to harmonize sleep and circadian studies in aging and Alzheimer’s disease.
In two large Alzheimer cohorts, a history of depression, anxiety, or PTSD and an increased number of psychiatric comorbidities were associated with earlier age at AD symptom onset by up to ~7–8 years for multi-morbidity.
This review evaluates recent evidence on plasma AD biomarkers, especially phosphorylated tau217 and amyloid PET, for predicting cognitive decline in unimpaired individuals, highlighting their potential and limitations.
This phase III trial evaluated oral valiltramiprosate in APOEε4/ε4 homozygotes with early Alzheimer’s, showing brain atrophy slowing but limited overall clinical benefit, with nominal improvements in mild cognitive impairment subgroup
This article elucidates how TREM2-apoE3 interactions are structurally altered by Alzheimer’s-associated TREM2 R47H and apoE4 variants, revealing potential mechanisms that contribute to disease risk and informing therapeutic targeting
Obicetrapib, a CETP inhibitor, lowers Alzheimer’s biomarkers like p-tau217 in ASCVD patients, especially ApoE4 carriers, suggesting a potential preventive strategy for high-risk individuals.
Pregnancy hypertension is independently associated with higher serum p-tau217 levels in midlife women, suggesting a link to preclinical Alzheimer’s disease pathology and potential for early screening and intervention.
This study compares five dementia risk indices using data from the HUNT study, revealing CogDrisk as the most accurate predictor, though none outperformed a demographics-only model including age and education.
Rapamycin shows promise in preventing Alzheimer’s disease in APOE4 carriers by improving brain mitochondrial function, synaptic activity, and vascular health, highlighting a potential genotype-targeted early intervention for this high
A 4-year longitudinal study reveals that long-duration, high-intensity lifetime walking is associated with reduced amyloid-β accumulation in older adults, suggesting a neuroprotective effect when initiated early in life.
Higher moderate-to-vigorous physical activity slows p-tau181 increase, a marker of Alzheimer’s pathology, but elevated p-tau181 diminishes exercise-related cognitive benefits in older adults.
This study links Alzheimer’s disease-related blood biomarkers with accelerated muscle strength loss over 12 years, highlighting the interplay between neurodegeneration and physical decline in aging populations.
This article reviews a systematic meta-analysis of 15 cerebrospinal fluid and blood biomarkers for Alzheimer’s disease, highlighting robust diagnostic performance of core markers T-tau, P-tau, and Aβ42 in clinical practice and researc
